Register for free to
view the full innovation profile.
DNA aptamer sequences that bind to alpha-synuclein monomers and inhibit formation of larger oligomers associated with neurodegenerative disease.
About
APTAMERS AS A THERAPEUTIC TOOL TO PREVENT PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASE Novel DNA aptamer sequences that bind to alpha-synuclein monomers and inhibit the formation of larger oligomers associated with neurodegenerative disease such as Parkinson’s Diseases. We have packaged the aptamers in a vehicle capable of crossing the blood brain barrier and binding to alpha synuclein in a mouse model of Parkinson’s disease. Immunofluorescence confirmed delivery of the fluorescently labelled aptamer and its co-localization with an antibody specific for phosphorylated alpha synuclein monomer. PCT application number: PCT/CA2018/051335 filed Oct. 22, 2018 US application number: 16/758,090 (int’l filing date 22-Oct-18) CA application number: 3,079,909 (int’l filing date 22-Oct-18) Inventor(s): DeRosa, Maria Cynthia; Holahan, Matthew Richard; McConnell, Erin Marie; Ventura, Katelyn Victoria; Callahan, Joshua Parker; Hunt, Vernon Harold Daniel Please contact Theresa White (Manager- Innovation Transfer) at [email protected] for more information. Image: Fdardel, CC BY-SA 3.0, via Wikimedia Commons
Key Benefits
• Compared with conventional antibodies, Aptamers are not typically recognized by the immune system and are neither immunogenic nor toxic molecule. • Aptamers can discriminate between different conformations of the same target protein. • Can be easily generated by chemical synthesis.